Life Sciences Archive » November, 2025

Life Sciences - November, 2025

218 articles

• Health Plans Defend Renewed Biogen MS Drug Scheme Suit
• Calif. Cannabis Workers Settle Suit Over Quotas, Lack Of Pay
• Paratek Beats Suit Alleging $462M Sale Built On D&O Interests
• GTCR Drops FTC Constitutional Challenge Over Merger Case
• Avantor Sued Over Supply Chain Issues After $6.4B Deal
• MVP: Ropes & Gray's Abigail Gregor
• Ex-Amarin CEO Loses Suit Over Ouster After Proxy Fight
• Yale Healthcare Workers Lose COVID Vaccine Mandate Suit
• Abbott Accused Of Miscalculating Workers' Overtime
• UnitedHealth Gets OptumRx Antitrust Suit Sent To Arbitration
• Medical AI Co. Accused Of 'Smear Campaign' Against Rivals
• Investors Say Alexandria Overhyped Leasing, NYC Project
• Considerations When Invoking The Common-Interest Privilege
• Mich. Pharmacist Gets 46 Months For $4M Fraud Scheme
• Judge Hands SEC Win In Pharma Co.'s CBD Investor Fraud Case
• MVP: Hogan Lovells' Mahvesh A. Qureshi
• NRDC Tells 9th Circ. EPA Would 'Neuter' Public TSCA Rights
• Mass. Judge Says States Can Fight Planned Parenthood Cuts
• DOJ Demand For Pa. Transgender Patient Records Blocked
• Full Fed. Circ. Rejects Bayer Petition In Xarelto Patent Case
• The Law Firm Merger Diaries: Making The Case To Combine
• Key Risks For Cos. As MAHA Influences Food Regulation
• State AGs May Extend Their Reach To Nat'l Security Concerns
• Hi-Tech Pharma CEO Beats Most Of Feds' Fraud Case
• Israeli Co. Can't Expand Contract Breach Suit Over $25M Deal
• Biotechs Go To Del. Chancery Over Cancer Drug Rights
• FTC Abandons In-House GTCR Merger Case After Court Loss
• MVP: Cooley's Charity Williams
• Ophthalmic Co. Hits Ch. 11 With $64M Debt, Eyeing Sale
• Justices Skip Appeal Challenging Denial Of Color TM
• Justices Refuse Drug Price-Fixing Class Action
• Squires Issues 57 More PTAB Denials, Broken Out By Type
• DC Judge Axes Teva Challenge To Drug Price Program
• Applied Therapeutics Investors Get 1st OK For $15M Deal
• PBMs Say Gov't Benefits From Drug Rebates FTC Condemns
• 'No Evidence' New Info Backs J&J Unit's Libel Suit, Court Told
• Despite Deputy AG Remarks, DOJ Can't Sideline DC Bar
• DLA Piper Adds Fenwick Emerging Growth, VC Expert In LA
• Key Strategies For Supplement Cos. Facing Lead Risks
• Bausch Health Financial Stability Suit Permanently Dismissed
• From Bank Loans To Private Credit: Tips For Making The Shift
• 3 Takeaways From FDA Cell And Gene Therapy Draft Guidance
• 1st Circ. Clears IT Co. In Suit Over Zoll Patient Data Breach
• Texas Sues Bristol-Myers For Alleged Drug Misrepresentations
• Invisalign-Maker's Sweetened $32M Antitrust Payout OK'd
• Pharma Cos. Seek Early Win In States' Price-Fixing Lawsuit
• Where Apple And Masimo's Watch Patent Fight Stands Now
• Teva, Cooper Cos. Argue FDA Approval Barred IUD Update
• FTC Withdraws In-House GTCR Merger Case
• How Cos. Should Prepare For Prop 65 Listing Of Bisphenols
• Claims Firms Barred From Misleading Plaintiffs In Pharma MDL
• Rule Amendments Pave Path For A Privilege Claim 'Offensive'
• IP Ownership Risk Grows In Booming Cancer Drug Market
• 2 Firms Guide Abbott's $23B Deal With Cologuard Maker
• My Miniature Livestock Farm Makes Me A Better Lawyer
• Is 'Red Book' Best For Drug Pricing? Pa. Justices Ask
• First Financial Says Medical Device Maker Owes $13.6M
• 23andMe Seeks OK For Ch. 11 Plan With Release Tweaks
• GTCR Wants FTC's In-House Merge Case Withdrawn Too
• Alkermes, Avadel Bump Deal To $2.37B After Alternate Bid
• Whoop Blood Pressure Tracker Hit With False Ad Suit
• Latham DQ'd From Sleep Apnea Device Co.'s Patent Fight
• In-House Atty From Teva Joins Spencer Fane's DC Office
• 8th Circ. Hears PBMs' Bid To Pause FTC Insulin Pricing Case
• Gilead Sciences' GC Will Leave Co. Next Month
• Surveying The Healthcare Policy Landscape Post-Shutdown
• FDA Biosimilar Guidance Should Ease Biologics Development
• Pfizer To Pay $41.5M To Settle Adulterated ADHD Drug Claims
• Ex-FDA Chief Accuses J&J Of Hiding Talc Risks For 50 Years
• J&J Unit Fights $12M Verdict While Rival Wants More Money
• Severe SC Abortion Bill Falters in Committee
• Feds Say Hi-Tech 'Trampled' Trust At Close Of Fraud Trial
• 23andMe Seeks OK On Updated $9M Settlement
• Merck Wins Final PTAB Fight Against Johns Hopkins
• Perrigo Sued Over Misstatements On Infant Formula Business
• Bristol-Myers Squibb Can Appeal Pension Suit To 2nd Circ.
• CVS Pays $18.2M To Settle False Claims Act Allegations
• 1st Circ. May Nix Trump Funding Freeze In 'Weird' Case
• Fed. Circ. Voids Allergan's $39M Trial Win Over Eyelash Patent
• IBM, Qualcomm Lead Public Cos. In Patented Inventions
• Purdue's $7.4B Ch. 11 Plan Jibes With New Release Paradigm
• Litigation Funding Could Create Ethics Issues For Attorneys
• Ill. Justices Mull If Permits Override Pollution Exclusions
• Lower Costs No Cause For VA To Shirk Trade Act, Judge Says
• Agilent Wants Justices To Eye Invalidation Of CRISPR Patents
• DC Circ. Mulls If Gov't Can Say No To 340B Rebate Program
• Advocacy Groups Push 9th Circ. To Uphold Fluoride Ruling
• B. Braun Unit Inks $38.5M Deal To End FCA Knee Implant Case
• 2nd Circ. Questions Experts' Rejection In Tylenol Autism Suits
• Medtronic Can't Nix FCA Claims Despite 1st Circ. Precedent
• Pa. Supreme Court Snapshot: Skill Games Top Nov. Lineup
• E-Discovery Quarterly: Recent Rulings On Dynamic Databases
• Cravath, Goodwin Advise On J&J's $3B Cancer Drug Play
• Lupin Drops Trade Secrets Case Against Rival
• Catching Up With Delaware's Chancery Court
• 3 Firms Advising On CD&R's $10.3B Bubble Wrap Maker Buy
• No High Court Review For FDA Fast-Track Denial
• Texas Judge Rejects Bid To Block Kenvue's $398M Dividend
• Amazon Blasts Claim It Destroyed Evidence In Labeling Suit
• Apple Hit By $634M Verdict Over Masimo Health Tech Patent
• ITC To Scrutinize Redesigned Apple Watch In Masimo IP Fight
• Ethiopian Importer Asks Court To Enforce $5M Arbitration Win
• Drug Buyers Defend Class Cert. In 3rd Circ. Generics Case
• Tricida Trustee Jackson Square Sues Over $740M Loss
• DOJ Official Among Trump Picks For District Courts
• DC Circ. Wary Of DEA Delays In Religious Ayahuasca Case
• How Litigating Antitrust Fix Helped GTCR Prevail In Court
• Taxation With Representation: Wachtell, Paul Hastings, Sidley
• Photographer Sues Gilead For Continued Use Of Ad Images
• Purdue's $7.4B Ch. 11 Plan To Be Confirmed
• Gibson Dunn, Cooley Guide Merck's $9.2B Cidara Buy
• J&J Bellwether Trial Over Talc Cancer Risks Kicks Off In LA
• Hemp Policy At Crossroads After Government Reopening Bill
• NC Biz Court Bulletin: Rulings Spotlight Coverage Clashes
• Weight-Loss Drug MDL In Pa. Grows With 3 New Jersey Cases
• Mich. Schools Sue Over Privacy Waiver In Funding Bill
• Fenwick, WilmerHale Steer $285M Mersana Take-Private Deal
• 3rd Circ. Says Quest Didn't Eavesdrop In Data Privacy Suit
• Wachtell-Led Pfizer Closes Metsera Deal Worth Up To $10B
• FTC Fails To Block Doctors' Testimony In $945M Merger Case
• Claims Firms Accused Of Misleading Plaintiffs In Pharma MDL
• Building With Lego Makes Me A Better Lawyer
• Biotech Co., Founders Can't Duck $14.3M SEC Payment
• Valsartan Cancer Expert Blocked, Ending First Injury Trial
• Sandoz Tells 3rd Circ. To Restore Full $137M Win Over UTC
• NJ Justices Keep Ozempic Injury Mass Torts Separate
• Purdue Kicks Off Ch. 11 Confirmation With Plan Overview
• Judge Confirms $620K Award In Radiology Contract Dispute
• 1st Circ. Weighs Federal Halt To Planned Parenthood Funding
• The Rise Of Trade Secret Specificity As A Jury Question
• China Continues To Drive Surge In Global Patent Applications
• Law School's Missed Lessons: Networking 101
• China National Gets Time Served For Smuggling Crop Fungus
• Judge Won't Halt Injunction Blocking Trump's Trans Care Ban
• Camp Lejeune Expert Criticism A Smear Tactic, Feds Say
• Defeating Estoppel-Based Claims In Legal Malpractice Actions
• Jones Day, Paul Hastings Guide $9.3B Filtration Group Deal
• Proposed Class Fights P&G Attempt To Transfer Tampon Case
• Law360 MVP Awards Go To Top Attorneys From 76 Firms
• GTCR's $627M Medical Coatings Acquisition Can Get Moving
• IRhythm Denied Early Win On Investor Scienter & Loss Claims
• Pfizer Again Asks Judge To Toss States' Price-Fixing Case
• Medtech Co-Founder Tells Chancery Father-Son Cut Him Out
• Novartis Argues For High Court To Skip Entresto Patent Case
• Trade Secret Rulings Reveal The Cost Of Poor Preparation
• FDA Lifts Hormone Replacement 'Black Box' Warnings
• FTC Risks Help Push Metsera Back To Pfizer
• The Biz Court Digest: How It Works In Massachusetts
• Chancery Drops Claims In Murder-Linked Bio Co. Merger Fight
• Catching Up With Delaware's Chancery Court
• 4th Circ. Opioid Case Brings Public Nuisance Back To The Fore
• States Say Macquarie Not Applicable To NH High Court Case
• Sleep Apnea Device Co. Investor Says Rollout Was Botched
• Spurned Pfizer Turns To Antitrust Law To Reclaim Biotech
• Canadian Co. Blocked From Using 'Deep Cleansing Oil' Brand
• Seattle Pot Shop Slapped With Site Tracking Pixel Privacy Suit
• USPTO Extends Deadline For PTAB Institution Rules Feedback
• Jury Clears Novo Nordisk Of Medicaid Fraud Over Blood Drug
• Fla. Judge Sentences HIV Drug Fraudster To 8 Years In Prison
• Merck Wins PTAB Fight Over Blockbuster Drug, Again
• Why Appellees Should Write Their Answering Brief First
• Taxation With Representation: Kirkland, Cravath, Paul Weiss
• Laborie Buys Postpartum Bleeding Device For Up To $465M
• Pair Of Health-Focused Startups Net $423M In Combined IPOs
• 'Send A Message' To Novo Nordisk Over Kickbacks, Jury Told
• CareFirst Urges Ban On J&J Character Talk At Stelara Trial
• Lilly, Novo Nordisk Enter Obesity Drug Price Deal With Trump
• Texas AG Wants To Halt Kenvue $400M Shareholder Pay
• Fla. AG Says Planned Parenthood Lied About Abortion Drugs
• FDA Warns Companies About Illegal Marketing Of Botox
• Squires Rebuffs Another 21 PTAB Petitions Without Comment
• Navigating DEA Quotas: Key To Psychedelics Industry Growth
• 3rd Circ. Won't Revive Investors' Suit Over Viatris Sale
• Med Groups Call To Break Up 'Politicized' CDC Vax Committee
• Edwards Defends $945M Heart Valve Deal From FTC Challenge
• Pfizer Matches Novo's $10B Metsera Bid, And Other Rumors
• Mindfulness Meditation Makes Me A Better Lawyer
• 1st Circ. Questions Trump Admin On NIH Indirect Cost Cuts
• Masimo Tells Jury It's Owed $749M In Apple Watch IP Fight
• 3 More Chinese Scholars Accused Of Smuggling Roundworms
• Squires Spurns Tesla PTAB Challenge Referred By Stewart
• Pharmacy Groups Urge 8th Circ. To Back Ark. PBM Limits
• Growth, Harmonization In Focus As Hague System Turns 100
• Celgene Inks $239M Investor Deal Over Drug Pipeline Claims
• Judge Lets Ex-MIT Lab Head's Defamation Case Move To Trial
• 9th Circ. Won't Rehear Biotronik Whistleblower Revival
• Lessons From 7th Circ. Decision Affirming $183M FCA Verdict
• FTC Wants 'Tainted' Drs. Testimony Barred From Merger Case
• Mich. AG Urges State High Court To OK Insulin Price Probe
• Chancery Won't Let Pfizer Block $10B Novo Bid For Metsera
• Biosciences Co. Didn't Infringe Cell Analysis IP, Judge Says
• Punitive Damages Awards Should Be Limited To 1st Instance
• How Calif. High Court Is Rethinking Forum Selection Clauses
• AI Litigation Tools Can Enhance Case Assessment, Strategy
• J&J, Kenvue Must Still Face IPO Fraud Claims, Judge Rules
• Industry Groups Want Trump Admin To Stop PTAB Changes
• Covington, Reed Smith Sue Vyaire Over Lost Fees
• Attys Beware: Generative AI Can Also Hallucinate Metadata
• End Payors Seek $66M In Atty Fees In Generic Drug MDL
• Novo Nordisk Boosts Metsera Bid To $10B After Pfizer Suit
• Pfizer Can't Freeze $9B Weight-Loss Drug Fight For Now
• Blackstone Injecting $700M Into Merck Cancer Therapy
• Pharmacies Seek Cert. In Cholesterol Drug Price-Fixing MDL
• Harvard Prof Says Novo's Influence Didn't Boost Prescriptions
• FDA Official Quits As Aurinia Sues Over 'Personal Vendetta'
• Biotech Co. Agrees To Reforms After Co-Founder's Conviction
• Squires' First Orders Reject PTAB Petitions En Masse
• Oncology Co. Board Hit With Suit Over Product Growth Claims
• Colorado Judge Denies AbbVie's Bid To Block State Drug Law
• Chancery Considers Reviewing Icahn's Illumina Settlement
• Doc Says No Duty To Preserve Emails Years Before Talc Suit
• Pfizer Hits Novo Nordisk In Fed. Court Over $9B Metsera Deal
• Fla. Pain Doc Was 'Pawn' In Kickback Scheme, 11th Circ. Told
• Lessons From Fed. Circ. On Expert Testimony In Patent Cases
• Bernstein Litowitz, Robbins Geller To Lead $8.9B Class Action
• Catching Up With Delaware's Chancery Court
• When Atty Ethics Violations Give Rise To Causes Of Action
• 4 Firms Guide $48.7B Kimberly-Clark Deal For Kenvue